Biotech company Neogap and cancer diagnostics company Simsen Diagnostics have initiated a collaboration aimed at improving personalized cancer diagnostics by examining circulating tumor DNA in the blood of patients participating in Neogap’s Phase I/II clinical trial. The goal is to…
Bioteknikbolaget Neogap och cancerdiagnostikbolaget Simsen Diagnostics har inlett ett samarbete inriktat på att förbättra individanpassad cancerdiagnostik genom att undersöka cirkulerande tumör-DNA i blodet hos patienter som deltar i Neogaps kliniska fas I Målet är att utveckla mer precisa och effektiva…
Gothenburg 2022-12-06 Simsen Diagnostics AB and Oncorena AB have entered into an agreement, where Simsen Diagnostics will measure circulating tumor DNA in Oncorena’s clinical phase I-II kidney cancer study. Simsen Diagnostics will design individualized tests that follow a unique mutation…